Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03984370
Other study ID # CKN-DASI-RYGB
Secondary ID 2019-001915-22
Status Completed
Phase Phase 2
First received
Last updated
Start date September 18, 2019
Est. completion date February 26, 2020

Study information

Verified date March 2020
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.


Description:

The Roux-En-Y gastric bypass (RYGB) has major health-promoting effects - reversing type-2-diabetes, improving dyslipidemia and inducing robust weight loss. However, several RYGB-individuals, post surgery, suffers from dumping syndrome and postprandial hyperinsulinemic hypoglycemia (PHH) due to the anatomical rearrangement of the gastro-intestinal system. Dasiglugaon (also known as (ZP4207) has shown great pharmacokinetic- and dynamic effects, compared to other glucagon analogues on the market, when administrated to hypoglycemic type-1-diabetics.

Therefore we aim to examine the effects of two different doses of dasiglucagon on the postprandial nadir plasma glucose concentration in RYGB-operated individuals suffering from PHH by use of a mixed meal test (MMT).

The study is designed as a double-blinded, randomised, 3-period, 3-treatment, crossover study comprising 3 separate treatment days in which participants will undergo an MMT along with one of the following double-blinded interventions:

1. Subcutaneous (sc) placebo (saline) injection

2. Sc injection with 80 μg dasiglucagon

3. Sc injection with 200 μg dasiglucagon


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date February 26, 2020
Est. primary completion date February 26, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Documented postprandial hypoglycaemia (<3.9 mmol/l) by 6-day CGM or during a MMT

- Documented plasma glucose concentration excursions >5.0 mmol/l by 6-day CGM or a MMT

- Haemoglobin levels for women >7.3 mmol/l and for men >8.3 mmol/l

- Ferritin >10 µg/l

- Cobalamin >150 pmol/l

- Fasting plasma glucose concentration within the range of 4.0-6.0 mmol/l CKN-DASI-RYGB protocol version 1.0 6

- Normal electrocardiogram (ECG)

- Negative urine human chorionic gonadotropin (hCG) (for fertile women)

Exclusion Criteria:

- Treatment with medication(s) affecting insulin secretion or any antidiabetic drugs

- Treatment with antipsychotics

- Current participation in another clinical trial with administration of investigational drug.

- Previous exposure to dasiglucagon (otherwise known as ZP4207)

- History of liver disease that is expected to interfere with the anti-hypoglycaemic action of glucagon (e.g. liver failure or cirrhosis).

- Pregnancy

- Breastfeeding

- Any factors that, in the opinion of the site principal investigator or clinical protocol chair, would interfere with the safe completion of the study, including medical conditions that may require hospitalization during the trial or allergy to the ingredients in the study drug.

Study Design


Intervention

Drug:
ZP4207
Abdominal SC administration
Other:
Placebo (saline)
Abdominal SC administration

Locations

Country Name City State
Denmark Center for Clinical Metabolic Research, Herlev-Gentofte Hospital Hellerup

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Gentofte, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nadir plasma glucose concentration within two hundred forty minutes after MMT Nadir plasma glucose concentration within two hundred forty minutes after MMT Two hundred forty minutes
Secondary Time from dasiglucagon administration to recovery (first plasma glucose value above the fasting plasma glucose level Time from dasiglucagon administration to recovery (first plasma glucose value above the fasting plasma glucose level Two hundred forty minutes
Secondary Time in hypoglycaemia (plasma glucose concentration <3.9 mmol/l) from study drug administration until 240 minutes Time in hypoglycaemia Two hundred forty minutes
Secondary Time below fasting plasma glucose level from study drug administration until two hundred forty minutes Time below fasting plasma glucose level Two hundred forty minutes
Secondary Area 1: the area above the glucose curve and below the fasting level from the time of study drug administration until glucose values reach the fasting level. Area 1 Two hundred forty minutes
Secondary Area 2: the area below the glucose curve and above the fasting level from the time glucose values reach the fasting level until 240 minutes. Area 2 Two hundred forty minutes
Secondary Edinburgh Hypoglycaemia Symptom Scale (EHSS) responses of the Edinburgh Hypoglycaemia Symptom Scale (EHSS) and early dumping symptoms based on likert scale one (absent) to seven (severe) t=zero to t=Two hundred forty minutes
Secondary The Dumping Severity Score (DSS). likert scale, zero (absent) to three (severe) t=zero to t=Two hundred forty minutes
Secondary Frequency and severity of adverse events and serious adverse events recorded during the meal test Frequency from t= minus thirty to t=Two hundred forty minutes
See also
  Status Clinical Trial Phase
Completed NCT03200782 - Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study N/A
Recruiting NCT05036317 - Empagliflozin for the Treatment of Postprandial Hypoglycemia Phase 3
Active, not recruiting NCT05174507 - Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes Phase 2
Completed NCT04330196 - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance. N/A
Recruiting NCT04720859 - Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) N/A
Completed NCT05676385 - Glucose Response to a Formula for Patients at Risk of Hypoglycaemia N/A
Completed NCT04836273 - Treatment of Post-bariatric Hypoglycaemia Phase 2
Completed NCT05513404 - The Scottish Fruit Study N/A
Completed NCT01162499 - Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia N/A
Recruiting NCT05401578 - Canakinumab for the Treatment of Postprandial Hypoglycemia Phase 3